コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 optogenetics to overcome critical hurdles in cancer immunotherapy.
2 bsets with properties critical for improving cancer immunotherapy.
3 tigen receptor (CAR) carriers for redirected cancer immunotherapy.
4 cer cells, providing a promising approach to cancer immunotherapy.
5 e of tumors, is a therapeutic target for the cancer immunotherapy.
6 ctive biomarker for efficacious responses to cancer immunotherapy.
7 ry diseases and for boosting the efficacy of cancer immunotherapy.
8 bolite adenosine is an emerging approach for cancer immunotherapy.
9 therapy represents a potential candidate for cancer immunotherapy.
10 umor agent and has potential applications in cancer immunotherapy.
11 r-targeting compounds access to the power of cancer immunotherapy.
12 f p-shRNA make it an attractive platform for cancer immunotherapy.
13 risk of inflammatory complications following cancer immunotherapy.
14 a proof of concept for targeting LATS1/2 in cancer immunotherapy.
15 is, is therefore also a potential target for cancer immunotherapy.
16 ting these cells may improve the efficacy of cancer immunotherapy.
17 s the design of safer TCR gene therapies for cancer immunotherapy.
18 d source of epitopes for use in vaccines and cancer immunotherapy.
19 clinical strategies using IFNs and MSCs for cancer immunotherapy.
20 insic dysfunction may be required to improve cancer immunotherapy.
21 umor-derived HSPs are in clinical trials for cancer immunotherapy.
22 s a novel, small molecule-based approach for cancer immunotherapy.
23 t generate CD62L-enriched NKTs for effective cancer immunotherapy.
24 ffectively engage myeloid effector cells for cancer immunotherapy.
25 ne common to all cancers and is a target for cancer immunotherapy.
26 malignancies represents a paradigm shift in cancer immunotherapy.
27 ble off-target toxicity of TNFSF ligands for cancer immunotherapy.
28 and has emerged as a therapeutic target for cancer immunotherapy.
29 gy has tremendous potential to contribute to cancer immunotherapy.
30 modified enhanced affinity TCR designed for cancer immunotherapy.
31 titumour efficacy of PD-L1 antibody-mediated cancer immunotherapy.
32 ities in harnessing memory-like NK cells for cancer immunotherapy.
33 may be used to create new opportunities for cancer immunotherapy.
34 rs and identify potential new strategies for cancer immunotherapy.
35 tinal content also influences the outcome of cancer immunotherapy.
36 atment, focusing on the flourishing field of cancer immunotherapy.
37 lopment as adjunct agents in CTL-based colon cancer immunotherapy.
38 hancing drugs should improve the efficacy of cancer immunotherapy.
39 re suitable platforms as novel adjuvants for cancer immunotherapy.
40 (+) T cells is of great clinical interest in cancer immunotherapy.
41 elanoma is a landmark for the development of cancer immunotherapy.
42 gens and encourages their implementation for cancer immunotherapy.
43 fore, survivin has potential as a target for cancer immunotherapy.
44 ritical checkpoint to effective T-cell-based cancer immunotherapy.
45 cific vaccine targeting XCR1(+) DCs to human cancer immunotherapy.
46 ests its potential clinical translation into cancer immunotherapy.
47 g antigen loading and exosome production for cancer immunotherapy.
48 immunity, thus offering a unique approach to cancer immunotherapy.
49 er immunosurveillance and may be targets for cancer immunotherapy.
50 cell therapies represent a turning point in cancer immunotherapy.
51 using gene mutations or engineer T cells for cancer immunotherapy.
52 ghlight new opportunities for CD4 T cells in cancer immunotherapy.
53 or the manipulation of gammadelta T cells in cancer immunotherapy.
54 acter of NK cells most desired for effective cancer immunotherapy.
55 g to tumors, a finding with implications for cancer immunotherapy.
56 the efficacy of NK cell-based approaches for cancer immunotherapy.
57 l) polymorphism as a potential predictor for cancer immunotherapy.
58 geting CTLA-4 have been successfully used as cancer immunotherapy.
59 e clinical studies that use antigen-specific cancer immunotherapy.
60 immunity remains a persistent impediment to cancer immunotherapy.
61 native adjuvant to CD47-targeting agents for cancer immunotherapy.
62 ntitumour immunity that can be exploited for cancer immunotherapy.
63 hod to empower DC vaccination approaches for cancer immunotherapy.
64 ity that they could influence the outcome of cancer immunotherapy.
65 nologic memory may offer effective tools for cancer immunotherapy.
66 hat manipulating the microbiota may modulate cancer immunotherapy.
67 ggesting that they may be targetable Ags for cancer immunotherapy.
68 as been the foundation for new approaches to cancer immunotherapy.
69 of antitumor immune responses and success of cancer immunotherapy.
70 s and can be manipulated to improve adoptive cancer immunotherapy.
71 ys inhibitory and suggest a new approach for cancer immunotherapy.
72 , creating formidable barriers to successful cancer immunotherapy.
73 or the manipulation of gammadelta T cells in cancer immunotherapy.
74 ng explored as therapeutics, most visibly in cancer immunotherapy.
75 rationale for targeting Tim-3 for effective cancer immunotherapy.
76 nd are a major focus in developing effective cancer immunotherapy.
77 t STING pathway, with major implications for cancer immunotherapy.
78 tic potential of targeting Chop in MDSCs for cancer immunotherapy.
79 SCs as a therapeutic modality for engineered cancer immunotherapy.
80 n of research and clinical opportunities for cancer immunotherapy.
81 for IL9 neutralization as a unique tool for cancer immunotherapy.
82 targeting the dynamism of Th17-Treg cells in cancer immunotherapy.
83 and justifies some current approaches toward cancer immunotherapy.
84 cytes is key to the development of effective cancer immunotherapy.
85 h may be manipulated to exploit NK cells for cancer immunotherapy.
86 re represent a major obstacle for successful cancer immunotherapy.
87 tion therapies are becoming a focal point in cancer immunotherapy.
88 targeting TEM1 has therapeutic potential in cancer immunotherapy.
89 er antigens and identify new tools for human cancer immunotherapy.
90 nse, which may provide new opportunities for cancer immunotherapy.
91 lpha may thus represent a novel approach for cancer immunotherapy.
92 safe and effective platform for CAR-directed cancer immunotherapy.
93 We are at a turning point for the field of cancer immunotherapy.
94 ating large numbers of cytotoxic T cells for cancer immunotherapy.
95 th additional immune-targeted strategies for cancer immunotherapy.
96 autoimmunity, inflammation, anaphylaxis, and cancer immunotherapy.
97 es and major ongoing studies in the field of cancer immunotherapy.
98 lls, providing a disease-specific target for cancer immunotherapy.
99 1 immunity makes them attractive targets for cancer immunotherapy.
100 nsidered if B7-H4 blockade is to be used for cancer immunotherapy.
101 unity, with a main emphasis on tolerance and cancer immunotherapy.
102 elevant to optimize innate-like T cell-based cancer immunotherapy.
103 umor immunity is indispensable for effective cancer immunotherapy.
104 tly one of the most promising approaches for cancer immunotherapy.
105 ceramide (alphaGC) may offer novel tools for cancer immunotherapy.
106 vo use as molecular vaccine adjuvants and in cancer immunotherapy.
107 iveness of conventional therapies as well as cancer immunotherapy.
108 een developed to harness 4-1BB signaling for cancer immunotherapy.
109 protein CD47 and a potential target of anti-cancer immunotherapy.
110 body Fc effector functions in the context of cancer immunotherapy.
111 tory functions and are of clear interest for cancer immunotherapy.
112 tors that warrant further investigation as a cancer immunotherapy.
113 trategy in boosting anti-tumour immunity for cancer immunotherapy.
114 nity and that cGAMP may be used directly for cancer immunotherapy.
115 specific T cells is critically important for cancer immunotherapy.
116 ociated antigens is a promising approach for cancer immunotherapy.
117 ing, which can be exploited for personalized cancer immunotherapy.
118 itors to selectively target Treg and improve cancer immunotherapy.
119 cations to generally improve the efficacy of cancer immunotherapy.
120 functions of this molecule in the context of cancer immunotherapy.
121 b is one of the most promising approaches to cancer immunotherapy.
122 and STAT3 signalling could be a strategy for cancer immunotherapy.
123 a promising new strategy within the field of cancer immunotherapy.
124 dvanced tumors remains a major challenge for cancer immunotherapy.
125 represents a promising new agent for future cancer immunotherapy.
126 -4 and PD-1/PD-L1 have advanced the field of cancer immunotherapy.
127 s are thus a robust platform for combination cancer immunotherapy.
128 in for efficient vaccine delivery and potent cancer immunotherapy.
129 s and was initially proposed as a target for cancer immunotherapy.
130 n presenting cells (APCs) in lymph nodes for cancer immunotherapy.
131 s may pave the way to a new era of precision cancer immunotherapy.
132 c antigen receptor (CAR)-modified T cells in cancer immunotherapy.
133 nanomedicines for its future applications in cancer immunotherapy.
134 ved understanding of the mechanisms limiting cancer immunotherapy.
135 is critical for opportunities in developing cancer immunotherapies.
136 d the development of gammadelta T cell-based cancer immunotherapies.
137 c seeds and potentiate macrophage-modulating cancer immunotherapies.
138 ay ultimately affect tumor responsiveness to cancer immunotherapies.
139 (TNFR) superfamily are emerging as promising cancer immunotherapies.
140 alternative to IL-2 for Vgamma9 T cell-based cancer immunotherapies.
141 -tumor factors that can be targeted to boost cancer immunotherapies.
142 ells and can thereby improve the efficacy of cancer immunotherapies.
143 r neoantigens and their use in personalizing cancer immunotherapies.
144 echanism of action for GITR agonist-mediated cancer immunotherapies.
145 g could lead to new, improved generations of cancer immunotherapies.
146 be important for the therapeutic efficacy of cancer immunotherapies.
147 into the first reproducible effective human cancer immunotherapies.
148 velopment of novel and objectively effective cancer immunotherapies.
149 ablishing the basis for novel individualized cancer immunotherapies.
150 ) is a dsRNA mimetic explored empirically in cancer immunotherapy a long time ago with little knowled
151 essive impact of CTLA4 and PD1-PDL1-targeted cancer immunotherapy, a large proportion of patients wit
152 to significantly enhance checkpoint blockade cancer immunotherapy, affording clinical benefits for th
154 These findings highlight the importance of cancer immunotherapies aiming to polarize tumor-associat
155 novel human NK cell-targeted and combinatory cancer immunotherapies and for studying how they elicit
156 , or mimotope vaccines, are commonly used in cancer immunotherapy and function by eliciting increased
159 cells from small blood or tissue samples for cancer immunotherapy and immune-monitoring purposes.
160 been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ult
161 tor-mediated trogocytosis on the efficacy of cancer immunotherapy and other mAb-based therapies.
162 rogenic functions of IDO can be targeted for cancer immunotherapy and present an overview of the curr
163 application of ex vivo expanded NK cells in cancer immunotherapy and provide a translational humaniz
164 that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the de
165 ndings represent a new powerful approach for cancer immunotherapy and suggest a general strategy for
166 igands should be considered in NK cell-based cancer immunotherapy and that our unique mouse models sh
167 f memory CD8(+) T cells (TM) is essential in cancer immunotherapy and the control of certain infectio
170 ikely to be critical for optimizing emerging cancer immunotherapies, and for the rational design of n
171 cations such as protein replacement therapy, cancer immunotherapy, and genomic engineering, their eff
172 sight into the activity of anti-CTLA-4-based cancer immunotherapy, and illustrate the importance of s
173 evelopment directed at HIV/AIDS eradication, cancer immunotherapy, and the treatment of Alzheimer's d
179 st promising tumor antigens for T-cell-based cancer immunotherapies are unmodified self-antigens.
180 that highlight how efficacy and toxicity of cancer immunotherapy are affected by patient variation,
185 very of novel kinase targets, and we explore cancer immunotherapy as a new and promising research are
186 ukin-15 (IL-15) has significant potential in cancer immunotherapy as an activator of antitumor CD8 T
187 our-specific mutations are ideal targets for cancer immunotherapy as they lack expression in healthy
188 Our study has important implications for cancer immunotherapy as we define key transcription fact
190 e development of new measures to improve IL2 cancer immunotherapy, as well as treatments for autoimmu
191 gy-dependent modulations of TH9 activity for cancer immunotherapy.Autophagy is a cellular process for
194 olecules are promising candidates for future cancer immunotherapies, because they are tumor specific
195 investigated in over 1000 clinical trials of cancer immunotherapy, but have shown limited efficacy.
196 ) are a major obstacle to promising forms of cancer immunotherapy, but tools to broadly limit their i
197 M1 has potential as a therapeutic target for cancer immunotherapy by immunizing immunocompetent mice
198 roles in human immunity to pathogens and in cancer immunotherapy by responding to isoprenoid metabol
199 he tumor-immune microenvironment and improve cancer immunotherapy by using lower "vascular normalizin
205 s is continuing based on clear evidence that cancer immunotherapy designed to overcome immune toleran
207 r immunity and suggest possibilities for new cancer immunotherapies directed at blocking CIS function
209 n address some of the emerging challenges in cancer immunotherapy, for example (i) enabling combinati
210 he anti-PD-L1 antibody MPDL3280A, a systemic cancer immunotherapy, for the treatment of metastatic UB
212 y suggest a rational design of combinatorial cancer immunotherapy harnessing DNA demethylation and IF
218 of negative checkpoint regulators (NCRs) for cancer immunotherapy has garnered significant interest w
223 vironment shapes the prognosis of colorectal cancer, immunotherapy has shown no benefit for the vast
226 h rapid expansion in clinical application of cancer immunotherapies, here we review the current state
227 view Series focus on current developments in cancer immunotherapy, highlight recent advances in our u
228 preclinical and clinical studies directed at cancer, immunotherapy, HIV eradication, and Alzheimer's
231 ts is proving to be an effective and durable cancer immunotherapy in a subset of patients with a vari
236 itro investigations for several mAbs used in cancer immunotherapy, including rituximab and ofatumumab
237 hat may influence response and resistance to cancer immunotherapy, including tumor mutational burden
238 nces in neoantigen quality might explain why cancer immunotherapy induces tumor regression in some in
246 high doses to activate the immune system in cancer immunotherapy, is now being repositioned to treat
247 rammed death 1 (PD-1), is being targeted for cancer immunotherapy, it is important to identify the ci
251 Promising recent developments suggest that cancer immunotherapy may become a powerful new therapy t
252 cacious application of A(2A)R inhibitors for cancer immunotherapy may require careful dose optimizati
254 e results provide a rationale of how to tune cancer immunotherapy more effectively in a hostile tumor
255 and improve T cell memory quality in current cancer immunotherapies proposing transient Treg cell abl
257 adjuvants to safely enhance the efficacy of cancer immunotherapy, radiotherapy, or 'immunogenic' che
259 pite its success in several clinical trials, cancer immunotherapy remains limited by the rarity of ta
261 site goal: in this field, we seek the Yin to cancer immunotherapy's Yang, and focus on manipulating T
265 roenvironment is critical for the success of cancer immunotherapies such as adoptive cellular transfe
267 mphomas and for the monitoring of successful cancer immunotherapies, such as adoptive cell transfer a
272 ti-vascular endothelial growth factor (VEGF) cancer immunotherapy targets angiogenesis but developmen
273 nvestigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in pat
276 ay to enhance the effectiveness of pediatric cancer immunotherapies through improved engineering of s
278 tolerance is a major obstacle to successful cancer immunotherapy; thus, developing strategies to bre
279 e immunosuppression, and as a new target for cancer immunotherapies to eliminate or reduce metastasis
280 ne escape from CTL, and they suggest a novel cancer immunotherapy to block PD-L1 expression in hypoxi
281 , Leber's Congenital Amaurosis Type 2 and in cancer immunotherapy trials for hematological malignanci
282 ria in Solid Tumours (RECIST version 1.1) in cancer immunotherapy trials, to ensure consistent design
285 discrete genomic determinants of response to cancer immunotherapy, unlike molecularly targeted therap
287 odulation of immune response is important in cancer immunotherapy, vaccine adjuvant development and i
288 ncept for CD5-2 as a therapeutic modifier of cancer immunotherapy via effects on the tumor vasculatur
289 in T cells and have clinical implications in cancer immunotherapy when anti-B7-H1 (PD-L1) antibody is
290 n-induced T cell death (RICD), especially in cancer immunotherapy, where highly proliferating T cells
291 ined prominence as a potential candidate for cancer immunotherapy, where it has been shown that in vi
292 ow to optimally modulate the PD-1 pathway in cancer immunotherapy while minimizing adverse events.
294 ew years will determine the extent of impact cancer immunotherapy will have on the treatment of the g
298 an attractive approach for the next phase of cancer immunotherapies, with a number of clinical trials
299 ular and genomic determinants of response to cancer immunotherapy, with an emphasis on immune checkpo
300 mmune response modulatory vaccine for active cancer immunotherapy without ex vivo manipulation, thus
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。